International Myeloma Working Group Recommendations for the Treatment of Patients with RRMM

2021 Year in Review - Multiple Myeloma —February 23, 2022

Categories:

Multiple Myeloma

The International Myeloma Working Group developed evidence-based clinical practice recommendations for the treatment of RRMM, with the goal to help guide real-world clinical practice and improve patient outcomes.

The International Myeloma Working Group developed evidence-based clinical practice recommendations for the treatment of patients with relapsed/refractory multiple myeloma (RRMM), which was published in the March 2021 issue of Lancet Oncology and summarized here.

Clinical considerations for patients with RRMM who have received 1 previous line of therapy, including whether the patient has lenalidomide-refractory disease and whether disease progression occurs with daratumumab-based regimens. Recommendations are below:

  • For patients not refractory to lenalidomide, preferred options (grade 1A recommendation) are daratumumab plus lenalidomide/dexamethasone or carfilzomib plus lenalidomide/dexamethasone. Alternative options (grade 1B recommendation) are daratumumab plus bortezomib/dexamethasone (DVd), carfilzomib/dexamethasone (Kd), daratumumab plus carfilzomib/dexamethasone (DKd), isatuximab plus carfilzomib/dexamethasone (Isa-Kd), ixazomib plus lenalidomide/dexamethasone, elotuzumab plus lenalidomide/dexamethasone, pomalidomide plus bortezomib/dexamethasone (PVd), or selinexor plus bortezomib/dexamethasone.
  • For patients with lenalidomide-refractory disease, switching from an immunomodulatory drug to a proteasome inhibitor is recommended. Preferred options (grade 1A recommendation) are PVd, DKd, or Isa-Kd. Alternative options (grade 1B recommendation) are DVd or Kd. Other options (grade 1C recommendation) are carfilzomib plus pomalidomide/dexamethasone (KPd), daratumumab plus pomalidomide/dexamethasone (DPd), or ixazomib plus pomalidomide/dexamethasone (Isa-Pd).

Recommendations for patients who are in second or higher relapse include:

  • Preferred options are any first relapse options that have not been tried, including Isa-Pd, DKd, DPd, Isa-Kd, elotuzumab plus pomalidomide/dexamethasone, or KPd. When daratumumab, carfilzomib, or elotuzumab are not available, pomalidomide plus cyclophosphamide/dexamethasone or pomalidomide/dexamethasone may be considered.
  • Alternative approved options include selinexor, addition of panobinostat to proteasome inhibitors, bortezomib/dexamethasone/thalidomide plus cisplatin/doxorubicin/cyclophosphamide/etoposide, belantamab mafodotin (4 lines).
  • Other options are investigational agents including melphalan flufenamide, B-cell maturation antigen–targeting agents, including chimeric antigen receptor T-cells or bispecific antibodies, and venetoclax in t(11;14) or BCL2-high expression.

These International Myeloma Working Group recommendations are expected to help guide real-world clinical practice with the goal of improving outcomes for patients with RRMM.

Source: Moreau P, Kumar SK, Miguel JS, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105-e118.

Related Articles
Multiple Myeloma Year in Review Introduction
2022 Year in Review - Multiple Myeloma
This edition of Year in Review is focused on multiple myeloma (MM), a disease for which the treatment landscape has seen tremendous growth resulting in major favorable changes in patient outcomes. New treatments have been approved and novel classes of agents continue to be investigated, particularly in the relapsed/refractory multiple myeloma (RRMM) setting. We are providing this Year in Review series to disseminate the latest information on treatment advances in 2022 to clinicians in a timely and effective manner.
Addition of ASCT to Triplet Induction and Lenalidomide Maintenance to Progression: Results from the DETERMINATION Trial
2022 Year in Review - Multiple Myeloma
The addition of ASCT to triplet induction with lenalidomide, bortezomib, and dexamethasone (RVd) and lenalidomide maintenance resulted in significant PFS benefit versus RVd alone.
Daratumumab + Cyclophosphamide, Bortezomib, and Dexamethasone Induction Followed by Daratumumab Maintenance Achieved Durable Responses in Patients with RRMM and NDMM
2022 Year in Review - Multiple Myeloma
Final results from LYRA demonstrated robust responses with dara + CyBorD induction, which deepened with dara maintenance.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country